An observational study in POLR2A Mutation, POLR2B Mutation and Neurodevelopmental Disorder (Diagnosis), sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Neurodevelopmental Disorders with a site in United States — 37 open to participants now, 53 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.
Among the 100 studies in Neurodevelopmental Disorders with a site in United States, this one is the 21st largest by planned enrollment of the 40 observational ones that give a count, is one of 11 that started in 2026, is one of 40 observational ones, reaches primary completion later than 30 of the 52 other live ones, and was the 100th registered.
355 studies on the registry are indexed under Neurodevelopmental Disorders; 144 are open to participants now.
Browse Neurodevelopmental Disorders studies →37 of the 100 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 6 mo+
Life University · Sites in United States
Ages 8+
UCB Biopharma SRL · Sites in United States, France, Spain
Ages up to 17
Healing Hope International · Sites in United States
Ages 4–12
GRIN Therapeutics, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 1 mo–18 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 13 · Phase 4 1
First in 1996; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 200 across 135 observational studies indexed under Neurodevelopmental Disorders.
Median enrollment 100 across the 60 interventional studies, 158 across the 40 observational. Of the 43 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 100 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 1 study filed under Neurodevelopmental Disorders — fewer than ten, so there is no comparison to draw.
19 of the studies in Neurodevelopmental Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06915480Phase 3Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Reducing Missed Appointments | 2026-12-31 |
| NCT07224581Phase 3GRIN Therapeutics, Inc.Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder | 2027-05 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT03770832Shirley Ryan AbilityLabWearable Sensors and Video Recordings to Monitor Motor Development | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 100 studies in Neurodevelopmental Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to study the natural history of patients with POLR2A or POLR2B variants to enable better understanding of the disorder, with the long-term goal of helping researchers plan future treatment studies.
Individuals with pathogenic variants in the POLR2A or POLR2B gene
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Affected participant, with anticipated or confirmed POLR2 genetic mutation
Define POLR2-related neurodevelopmental disorder
Describe the spectrum, frequency, age of onset, severity, and longitudinal evolution of clinical features, management, and outcomes in individuals with POLR2A or POLR2B related disorders.
Time frame: 3-years
Disease progression
To define longitudinal trajectories of disease progression using both non-concurrent data, including historical medical records, diagnostic reports, imaging, laboratory results, genetic testing reports, and other standard-of-care data, and concurrent data collected prospectively through real-world follow-up, clinical assessments, and biospecimen collection.
Time frame: 3-years
Genotype-phenotype correlations
To establish genotype-phenotype correlations based on the affected gene, variant type, variant location, inheritance pattern, predicted molecular consequence, and clinical severity.
Time frame: 3-years
Characterize comorbidities
To characterize the prevalence, severity, age of onset, and clinical impact of medical comorbidities and organ-system involvement.
Time frame: 3-years
Describe clinical care
To describe clinical management patterns, healthcare utilization, surveillance practices, supportive interventions, quality-of-care indicators, and variability or gaps in care.
Time frame: 3-years
Evaluate associations in disease management and outcomes
To evaluate associations between management strategies and clinical outcomes in an observational framework.
Time frame: 3-years
Identify outcomes for interventional clinical trials
To identify candidate clinical outcome assessments, patient- and caregiver-reported outcomes, functional measures, disease milestones, biomarkers, and endpoints that may support future interventional clinical trials.
Time frame: 3-years
Registry formation
To develop and maintain a coded registry of individuals with POLR2-related neurodevelopmental disorder to support longitudinal follow-up, future recontact, recruitment for research studies, and clinical trial readiness.
Time frame: 3-years
Test standardized clinical outcome assessments
To evaluate the feasibility, tolerability, and longitudinal utility of standardized developmental, rehabilitation, gait, neuropsychological, adaptive behavior, and quality-of-life measures as candidate clinical outcome assessments for POLR2-related neurodevelopmental disorder.
Time frame: 3-years
Characterize physical and rehabilitation impacts
To characterize motor function, manual dexterity, gait, mobility, adaptive behavior, cognition, participation, and caregiver/family impact over a 2-3 year follow-up period.
Time frame: 3-years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Participants may be recruited by Mayo Clinic physicians or other study staff. Recruitment may also be supported through Dr. Craig Kaplan's University of Pittsburgh registry, "POLR2A and related POLR2 Patient Registry." Dr. Kaplan may serve as an external referring provider because of his involvement in POLR2 research. Any sharing of participant-identifying information between Mayo Clinic and the University of Pittsburgh will occur only as permitted by participant consent/authorization and under an appropriate data use or similar agreement. Professor William Murphy, an external collaborator in Biomedical Engineering at the University of Wisconsin, may receive coded human biospecimens to support organoid development and related gene-delivery or therapeutic research. Any transfer of specimens or associated information will occur only under appropriate institutional agreements and in accordance with participant consent/authorization. Participants who do not consent to sharing informat
Supporting information: Study protocol, Informed consent form
Time frame: Start date of data sharing is 01/01/2027, until data collection has ceased.
Access criteria: Identifiable information (PHI) will be shared with Crag Kaplan and the University of Pittsburgh Registry. Samples and non-identifiable information will be shared with William Murphy and University of Wisconsin
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Of 67 non-industry observational studies under Neurodevelopmental Disorders, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 101. This study's planned 13 months is below that.
Counting every sponsor, half of 70 studies reached it within 59 months; a quarter within 32 and three quarters within 101.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurodevelopmental Disorders →